IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
28.10.2025 21:04:00 CET | Business Wire | Press Release
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced it will integrate NVIDIA’s NVQLink into its quantum computers to scale error correction, a key component for realising quantum computing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028095798/en/
IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
NVQLink is an open and interoperable platform integrated with NVIDIA CUDA-Q that connects quantum hardware to AI supercomputing. It provides low-latency and high-throughput connectivity between quantum computers and Graphics Processing Unit (GPU)-accelerated compute, enabling the real-time orchestration of computational tasks needed for running useful hybrid quantum-classical applications and quantum error correction.
While today’s quantum computers are reaching sizes that unlock algorithms in simulation, optimization, and machine learning, errors at the level of physical qubits still prevent commercial quantum advantage.
IQM’s technology roadmap focuses on quantum error correction, which reduces error rates by encoding logical qubits in clusters of physical qubits. This requires longer runtimes, and more complex compute processes on GPUs. To support this path, IQM has pioneered IQM Constellation, a unique quantum processor architecture for scalable error correction.
The partnership combines IQM’s system integration know-how and advanced processor technology, Zurich Instruments’ control systems, and the NVIDIA accelerated computing platform with scaling compute power across the timescales involved from hundreds of nanoseconds to seconds. As a result, this collaboration establishes a layered compute architecture capable of supporting workloads.
“Integrating NVQLink into our systems is a significant step towards building logical qubits and utility-scale quantum computers,” said Jan Goetz, Co-CEO and Co-founder of IQM Quantum Computers. “By combining our IQM Constellation with NVIDIA accelerated computing and Zurich Instruments’ control electronics, we can tackle one of the toughest challenges on the road to fault-tolerant quantum computing: real-time decoding and control at scale.”
Beyond error correction, NVQLink also supports hybrid quantum–classical applications by allowing seamless data flow between logical qubits and classical compute resources. This opens up new opportunities for running hybrid algorithms that require real-time feedback from large-scale compute to superconducting quantum computers.
“Quantum is reaching an inflection point, and hybrid systems will be the foundation for solving real-world problems,” said Flavio Heer, CTO at Zurich Instruments. “Collaborating closely with IQM and NVIDIA to showcase seamless end-to-end integration of classical and quantum computing, spanning both hardware and software, represents a significant advancement for hybrid classical-quantum systems, and will enable powerful demonstrations very soon.”
"Building scalable quantum accelerated supercomputing demands tighter integration between quantum processors and classical accelerated computing to tackle challenges like quantum error correction," said Tim Costa, General Manager for Quantum at NVIDIA. "QPU builders like IQM and quantum system vendors like Zurich Instruments are accelerating breakthroughs in quantum computing by using NVIDIA NVQLink as the open unified interface connecting quantum hardware to accelerated computing platforms."
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States. For more information, visit: meetiqm.com
About Zurich Instruments
Zurich Instruments is a Swiss company with a passion for phenomena that are often notoriously difficult to measure. We lead the change by providing advanced hardware, software and services for quantum computing control systems, lock-in amplifiers, impedance analyzers, and arbitrary waveform generators. As a company of scientists for scientists, we tackle challenges of research by delivering a wide product portfolio that reduces complexity of laboratory setups, unlocks new measurement strategies and complies to Swiss quality standards. Our commitment to collaborations and real-time support is reflected in seven offices worldwide, numerous research partnerships, and thousands of publications referring to Zurich Instruments. Since 2021, Zurich Instruments is a part of the Rohde & Schwarz and continues its scale up ambitions to advance science and accelerate the second quantum revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028095798/en/
Contacts
Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom